Kymera Therapeutics, Inc.
KYMR
Updated: 22/09/2026, 23:57:59
Kymera Therapeutics, Inc. is a biopharmaceutical company dedicated to discovering and developing pioneering small molecule therapeutics. These treatments operate by harnessing the body's inherent protein degradation system to selectively eliminate disease-causing proteins. The company's pipeline features several programs, including the IRAK4 program, currently in Phase I clinical trials, which targets various immunology-inflammation disorders such as hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, generalized pustular psoriasis, and rheumatoid arthritis. Additionally, Kymera is advancing its IRAKIMiD program, designed to address MYD88-mutated diffuse large B cell lymphoma. Other key programs include the STAT3 program, focused on hematological malignancies, solid tumors, autoimmune diseases, and fibrosis, as well as the MDM2 program, which is also aimed at hematological malignancies and solid tumors. The company was founded in 2015 and maintains its headquarters in Watertown, Massachusetts.
No summaries found.
- Share price
- $122.06
- Market cap
- $10.04B
- Exchange
- NASDAQ
- Currency
- USD
- CEO
- Nello Mainolfi
- Employees
- 273
- IPO date
- 21/08/2020
- Beta
- 1.965
- Last dividend
- $0.00
- Day range
- $118.90 – $122.34
- 52-week range
- $50.35 – $130.05
- 1-day performance
- 3.73%
- 1-year performance
- 142.42%
- Current drawdown (1Y)
- -6.14%
- CIK
- 0001815442
- CUSIP
- 501575104
- ISIN
- US5015751044
- Created
- 07/12/2025, 05:00:28
- Last update
- 22/09/2026, 23:57:59
Track Kymera Therapeutics, Inc. with an AI analyst
See which prediction-market events move KYMR, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.
Free forever to follow AlphaBrain’s AI strategies. No card required.
Kymera Therapeutics Presents Phase 1 Data in Healthy Japanese Adults for KT-621, a First-in-Class Oral STAT6 Degrader, at the Japanese Dermatological Association Annual Meeting
GlobeNewsWire • STOCK • 12/06/2026, 09:00:00
KYMR Stock Gains as KT-485 Starts Patient Dosing in HS Study
Zacks Investment Research • STOCK • 10/06/2026, 13:51:05
Kymera Therapeutics Appoints Penny Carlson as Senior Vice President, Development Operations
GlobeNewsWire • STOCK • 08/06/2026, 18:01:00
Kymera Therapeutics Announces Presentations on KT-621, a First-In-Class, Oral STAT6 Degrader, at the Society for Investigative Dermatology and American Thoracic Society Congresses
GlobeNewsWire • STOCK • 15/05/2026, 09:00:00
Kymera Therapeutics, Inc. (KYMR) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Seeking Alpha • STOCK • 12/05/2026, 16:50:44
KYMR Q1 Earnings Top Estimates, Revenues Gain on GILD Collaboration
Zacks Investment Research • STOCK • 01/05/2026, 17:10:12
Kymera Therapeutics, Inc. (KYMR) Q1 2026 Earnings Call Transcript
Seeking Alpha • STOCK • 30/04/2026, 15:51:37
Kymera Therapeutics, Inc. (KYMR) Reports Q1 Loss, Tops Revenue Estimates
Zacks Investment Research • STOCK • 30/04/2026, 11:35:23
KYMR Stock Up as FDA Grants Fast Track Designation to Asthma Drug
Zacks Investment Research • STOCK • 14/04/2026, 15:41:08
Kymera: 'Strong Buy' On Continued Success With KT-621 In Th2-Driven Disorders
Seeking Alpha • STOCK • 13/04/2026, 17:12:18
Kymera Therapeutics Presents KT-621 BroADen Data in Late-Breaking Research Session at the American Academy of Dermatology (AAD) Annual Meeting
GlobeNewsWire • STOCK • 28/03/2026, 12:00:00
Kymera Therapeutics, Inc. (KYMR) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Seeking Alpha • STOCK • 12/03/2026, 14:12:25